Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Mireille Gillings"'
Autor:
Shinya Rai, Won Seog Kim, Kiyoshi Ando, Ilseung Choi, Koji Izutsu, Norifumi Tsukamoto, Dai Maruyama, Kunihiro Tsukasaki, Junya Kuroda, Jun Ando, Michihiro Hidaka, Youngil Koh, Hisashi Kato, Toshiki Uchida, Deok Hwan Yang, Kenji Ishitsuka, Kenichi Ishizawa, Jin Seok Kim, Hong Ghi Lee, Hironobu Minami, Hyeon Seok Eom, Mitsutoshi Kurosawa, Jae Hoon Lee, Jong Seok Lee, Won Sik Lee, Hirokazu Nagai, Takero Shindo, Dok Hyun Yoon, Shinichiro Yoshida, Mireille Gillings, Hiroshi Onogi, Kensei Tobinai
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/be870e753e614a74b756e1f3d6e51924
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-17 (2021)
Abstract Background Treatment with immune checkpoint inhibitors (ICIs) targeting CTLA-4 and the PD-1/PD-L1 axis is effective against many cancer types. However, due in part to unresponsiveness or acquired resistance, not all patients experience a dur
Externí odkaz:
https://doaj.org/article/82617a89986343a6a08c52f9f5ac5da5
Autor:
Shinya Rai, Won Seog Kim, Kiyoshi Ando, Ilseung Choi, Koji Izutsu, Norifumi Tsukamoto, Masahiro Yokoyama, Kunihiro Tsukasaki, Junya Kuroda, Jun Ando, Michihiro Hidaka, Youngil Koh, Hirohiko Shibayama, Toshiki Uchida, Deok Hwan Yang, Kenji Ishitsuka, Kenichi Ishizawa, Jin Seok Kim, Hong Ghi Lee, Hironobu Minami, Hyeon Seok Eom, Mitsutoshi Kurosawa, Jae Hoon Lee, Jong Seok Lee, Won Sik Lee, Hirokazu Nagai, Takero Shindo, Dok Hyun Yoon, Shinichiro Yoshida, Mireille Gillings, Hiroshi Onogi, Kensei Tobinai
Publikováno v:
Haematologica, Vol 108, Iss 3 (2022)
Tucidinostat (formerly known as chidamide) is an orally available, novel benzamide class of histone deacetylase (HDAC) inhibitor that selectively blocks class I and class IIb HDAC. This multicenter phase IIb study aimed to investigate the efficacy an
Externí odkaz:
https://doaj.org/article/1f6b47ace5124b24847722a0557d0ba2
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
HBI-8000 is a small molecule inhibitor of class I HDACs and has been approved for the treatment of PTCL, ATL and, in combination with exemestane, in a subpopulation of breast cancer. Given the roles of HDACs in normal and cancerous cells, there are c
Externí odkaz:
https://doaj.org/article/6ca3c477813b4ec98437d652ef9e477d
Autor:
Joseph Markowitz, Siqing Fu, Gregory Daniels, Lyudmila Bazhenova, Nikhil Khushalani, Zeynep Eroglu, Andrew Brohl, Heather Yeckes-Rodin, Lori McCormick, Michael Kurman, Mireille Gillings, Gloria Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/f3529437fa1743ff965769eda42b8587
Autor:
Atae Utsunomiya, Koji Izutsu, Tatsuro Jo, Shinichiro Yoshida, Kunihiro Tsukasaki, Kiyoshi Ando, Ilseung Choi, Yoshitaka Imaizumi, Koji Kato, Mitsutoshi Kurosawa, Shigeru Kusumoto, Takashi Miyagi, Eiichi Ohtsuka, Osamu Sasaki, Hirohiko Shibayama, Kazuya Shimoda, Yasushi Takamatsu, Kuniko Takano, Kentaro Yonekura, Shinichi Makita, Jun Taguchi, Mireille Gillings, Hiroshi Onogi, Kensei Tobinai
Publikováno v:
Cancer Science. 113:2778-2787
This multicenter, prospective phase IIb trial evaluating the efficacy and safety of tucidinostat (HBI-8000) in patients with relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATLL) was undertaken in Japan. Eligible patients had R/R ATLL an
Autor:
Harry D Green, Samuel WD Merriel, Richard A Oram, Katherine S Ruth, Jessica Tyrrell, Samuel E Jones, Chrissie Thirlwell, Mireille Gillings, Michael N Weedon, Sarah ER Bailey
Publikováno v:
Green, H D, Merriel, S WD, Oram, R A, Ruth, K S, Tyrrell, J, Jones, S E, Thirlwell, C, Gillings, M, Weedon, M N & Bailey, S ER 2022, ' Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank ', British Journal of Cancer, vol. 127, pp. 1534–1539 . https://doi.org/10.1038/s41416-022-01918-z
ObjectivesTo assess how accurately a genetic risk score (GRS) can identify incident prostate cancer in men seeing their general practitioner with lower urinary tract symptoms.DesignCohort study.SettingUK Biobank data linked to primary care records.Pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fc9b85a19f28b9818bd96c340ebd9a3
http://hdl.handle.net/10138/353927
http://hdl.handle.net/10138/353927
Autor:
Makoto Yoshimitsu, Kiyoshi Ando, Takashi Ishida, Shinichiro Yoshida, Ilseung Choi, Michihiro Hidaka, Yasushi Takamatsu, Mireille Gillings, Gloria T Lee, Hiroshi Onogi, Kensei Tobinai
Publikováno v:
Japanese journal of clinical oncology. 52(9)
Objective HBI-8000 (tucidinostat) is a novel, oral histone deacetylase inhibitor that selectivity inhibits Class I (histone deacetylase 1, 2, 3) and Class II (histone deacetylase 10) with direct anti-tumor activity through various mechanisms of actio
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-17 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-17 (2021)
BackgroundTreatment with immune checkpoint inhibitors (ICIs) targeting CTLA-4 and the PD-1/PD-L1 axis is effective against many cancer types. However, due in part to unresponsiveness or acquired resistance, not all patients experience a durable respo
Autor:
Farbod Shojaei, J E. Semple, Che Fang, Jill M. Ricono, Fairooz Kabbinavar, Bob Goodenow, Mireille Gillings
Publikováno v:
Cancer Research. 82:LB526-LB526
92130MLL1 (mixed lineage leukemia1) interaction with WDR5 (WD repeat domain 5) is critical for MLL1 histone methyl transferase (H3K4me) activity leading to transcriptional regulation of gene expression. MLL1 dysregulation such as its translocation at